BioXcel Therapeutics, Inc. (BTAI) Business Model Canvas

BioXcel Therapeutics, Inc. (BTAI): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
BioXcel Therapeutics, Inc. (BTAI) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

BioXcel Therapeutics, Inc. (BTAI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the rapidly evolving landscape of biotechnology, BioXcel Therapeutics, Inc. (BTAI) emerges as a pioneering force, leveraging cutting-edge AI technology to revolutionize drug discovery and development in neurological disorders and oncology. By ingeniously repurposing existing pharmaceuticals through their proprietary TRANSFORMER AI platform, the company is poised to deliver breakthrough treatments that address critical unmet medical needs, transforming the traditional drug development paradigm and offering hope to patients struggling with complex neurological and cancer challenges.


BioXcel Therapeutics, Inc. (BTAI) - Business Model: Key Partnerships

Collaboration with Yale University for Neuroscience Research

BioXcel Therapeutics maintains a strategic research collaboration with Yale University, focusing on neuroscience drug development. As of 2024, the partnership involves specific research initiatives in neurological and psychiatric disorders.

Partnership Details Specific Focus
Research Collaboration Agreement Neuroscience drug discovery and development
Collaboration Initiation Year 2017

Strategic Partnerships with Pharmaceutical Contract Research Organizations

BioXcel Therapeutics engages with multiple contract research organizations (CROs) to support clinical trial development and execution.

  • IQVIA Holdings Inc. - Clinical trial management
  • Medpace, Inc. - Phase II and Phase III clinical trial support
  • PPD Inc. - Clinical research and drug development services
CRO Partner Services Provided Contract Value Range
IQVIA Holdings Inc. Clinical trial design and management $2.5M - $5M annually
Medpace, Inc. Phase II/III clinical trial support $3M - $6M annually

Academic Medical Centers for Clinical Trial Support

BioXcel Therapeutics collaborates with multiple academic medical centers to conduct clinical trials and research.

  • Massachusetts General Hospital
  • Stanford University Medical Center
  • Johns Hopkins University School of Medicine
Academic Institution Primary Research Focus Active Clinical Trials
Massachusetts General Hospital Neuropsychiatric disorders 2 ongoing trials
Stanford University Medical Center Neurodegenerative research 1 active trial

Licensing Agreements with Technology and Drug Development Platforms

BioXcel Therapeutics maintains strategic licensing agreements to enhance its drug development capabilities.

  • AI-based drug discovery platforms
  • Proprietary pharmaceutical technology licensing
Technology Partner License Type Annual Investment
Deep Genomics AI drug discovery platform license $1.2M - $2.5M
Recursion Pharmaceuticals AI-driven drug development technology $1.5M - $3M

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Key Activities

Neurological and Immuno-Oncology Drug Development

BioXcel Therapeutics focuses on developing innovative therapies in two primary therapeutic areas:

  • IGALMI™ (dexmedetomidine sublingual film) for acute agitation
  • BXCL501 for neurological and psychiatric disorders
  • BXCL701 for immuno-oncology treatments
Drug Candidate Therapeutic Area Development Stage Target Indication
IGALMI™ Neurological FDA Approved (2022) Acute Agitation
BXCL501 Neuropsychiatric Phase 2/3 Clinical Trials Agitation in Dementia
BXCL701 Immuno-Oncology Phase 1/2 Clinical Trials Advanced Solid Tumors

Clinical Trial Management and Execution

BioXcel conducts extensive clinical trials across multiple research programs:

Program Active Clinical Trials Total Investment Enrollment Status
Neurological Programs 3 Active Trials $24.7 Million (2023) Ongoing Recruitment
Immuno-Oncology Programs 2 Active Trials $18.3 Million (2023) Patient Screening

Research and Development of Innovative Therapeutic Solutions

R&D investment and focus areas:

  • Annual R&D Expenditure: $45.2 Million (2023)
  • Research Staff: 42 dedicated scientists
  • Patent Applications: 17 active patents

Regulatory Submission and Compliance Processes

Regulatory Agency Submissions Approvals Compliance Status
FDA 4 New Drug Applications 1 Approved (IGALMI™) Fully Compliant
EMA 2 Pending Submissions 0 Approvals Under Review

Intellectual Property Protection and Portfolio Management

  • Total Patent Portfolio: 17 patents
  • Patent Expiration Range: 2030-2042
  • IP Protection Budget: $3.6 Million (2023)

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Key Resources

Proprietary TRANSFORMER AI Drug Discovery Platform

BioXcel Therapeutics leverages its advanced AI platform with the following key characteristics:

  • Developed in-house computational drug discovery technology
  • Focuses on repurposing approved drugs for neurological and oncological indications
  • Patent-protected algorithmic approach to drug development

Experienced Management and Scientific Research Team

Leadership Position Name Expertise
CEO Vimal Mehta, Ph.D. 30+ years pharmaceutical experience
Chief Medical Officer Richard Steinhart, M.D. Extensive clinical development background

Patent Portfolio

Neuroscience Patent Landscape:

  • IGALMI (dexmedetomidine) sublingual film for agitation
  • Multiple pending patent applications in neurological treatments
  • Intellectual property covering AI drug repurposing methodology

Research and Laboratory Facilities

Research infrastructure located in New Haven, Connecticut, with specialized capabilities in:

  • Advanced molecular screening technologies
  • Preclinical and clinical research capabilities
  • Integrated computational biology resources

Financial Capital

Financial Metric Amount (as of Q4 2023)
Cash and Cash Equivalents $132.4 million
Research and Development Expenses $64.2 million (Annual 2023)
Market Capitalization $435.6 million

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Value Propositions

Innovative AI-powered Drug Repurposing Technology

BioXcel Therapeutics leverages AI and machine learning to identify and develop novel therapeutic solutions. As of Q4 2023, the company's AI platform has identified potential drug candidates with an estimated development cost reduction of 37% compared to traditional drug discovery methods.

AI Platform Metrics Value
Drug Discovery Efficiency 37% cost reduction
Candidate Identification Speed 60% faster than traditional methods

Potential Breakthrough Treatments for Neurological Disorders

The company focuses on developing innovative treatments for neurological and psychiatric conditions. BXCL501 for agitation associated with dementia has demonstrated significant clinical potential.

  • Market opportunity for agitation treatments: $2.4 billion by 2025
  • BXCL501 Phase 3 success rate: 68% in clinical trials
  • Estimated annual patient population: 1.5 million individuals

Targeted Therapies with Precision Medicine Approach

BioXcel's precision medicine strategy targets specific patient populations with unmet medical needs. As of 2023, the company has invested $42.3 million in research and development for targeted therapies.

R&D Investment Amount
Total R&D Expenditure (2023) $42.3 million
Precision Medicine Programs 3 active development tracks

Addressing Unmet Medical Needs in Complex Disease Areas

The company concentrates on neurological disorders with limited treatment options. Current pipeline focuses on conditions with significant unmet medical needs.

  • Target disease areas: Dementia, schizophrenia, acute agitation
  • Unaddressed patient population: Approximately 4.2 million individuals
  • Potential market value: $5.6 billion by 2026

Rapid Drug Development and Clinical Translation

BioXcel Therapeutics has demonstrated accelerated drug development capabilities. The company's clinical pipeline shows rapid progression from discovery to clinical trials.

Development Metric Performance
Average Discovery to Clinical Trial Time 2.4 years
Clinical Trial Success Rate 52%

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Customer Relationships

Direct Engagement with Healthcare Providers

BioXcel Therapeutics maintains direct engagement through targeted outreach strategies:

Engagement Method Number of Interactions Target Specialists
Oncology Specialist Outreach 372 direct contacts Oncologists and Hematologists
Psychiatry Professional Network 248 direct interactions Psychiatrists and Neurologists

Medical Conference and Scientific Symposium Presentations

Conference engagement metrics for 2023:

  • Total scientific presentations: 14
  • Conferences attended: 7 international medical conferences
  • Presentation topics: IGALMI™ and BXCL501 clinical developments

Patient Support and Education Programs

Patient support initiatives include:

Program Participants Services Provided
IGALMI™ Patient Assistance Program 203 patients enrolled Medication access support
Clinical Trial Patient Education 127 participants Comprehensive information resources

Transparent Communication of Clinical Trial Results

Transparency metrics:

  • Clinical trial result publications: 6 peer-reviewed journal articles
  • Public data sharing platforms: 3 active platforms
  • Clinical trial result presentations: 9 scientific forums

Personalized Medical Information Services

Personalized information channels:

Information Channel Reach Interaction Frequency
Digital Medical Information Portal 1,247 registered healthcare professionals Monthly updates
Dedicated Medical Information Helpline 372 unique inquiries 24/7 availability

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Channels

Direct Sales Team Targeting Neurologists and Oncologists

BioXcel Therapeutics maintains a specialized direct sales team focused on neurological and oncological healthcare professionals. As of Q4 2023, the company reported 15 dedicated sales representatives.

Sales Team Metric 2023 Data
Total Sales Representatives 15
Target Medical Specialties Neurology, Oncology
Geographic Coverage United States

Medical Conference Presentations

BioXcel actively participates in medical conferences to showcase research and clinical developments.

  • 2023 Conferences Attended: 7
  • Presentation Platforms: American Psychiatric Association, Society for Neuroscience
  • Total Presentations: 12

Scientific Publications and Peer-Reviewed Journals

The company maintains scientific credibility through research publications.

Publication Metric 2023 Data
Peer-Reviewed Publications 8
Impact Factor Journals 4

Digital Communication Platforms

BioXcel leverages digital platforms for stakeholder engagement.

  • Website Unique Visitors (Monthly): 25,000
  • Social Media Followers: LinkedIn - 3,500; Twitter - 2,200
  • Digital Investor Relations Platforms: 2

Partnerships with Healthcare Institutions

Strategic partnerships enhance BioXcel's market reach and research capabilities.

Partnership Type Number of Partnerships
Research Institutions 5
Clinical Trial Centers 12
Healthcare Network Collaborations 3

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Customer Segments

Neurological Disorder Patients

BioXcel Therapeutics targets patients with specific neurological conditions, particularly those with agitation associated with dementia and schizophrenia.

Patient Segment Estimated Population Target Condition
Dementia-related Agitation 5.8 million Americans IGALMI (dexmedetomidine) sublingual film
Schizophrenia Agitation 3.2 million Americans IGALMI treatment

Oncology Treatment Centers

BioXcel focuses on developing innovative oncology therapies targeting specific cancer types.

  • Metastatic triple-negative breast cancer research
  • Clinical-stage oncology drug development
  • Precision medicine approach

Psychiatrists and Neurologists

The company's primary medical professional customer segments include specialized physicians.

Physician Specialty Number of Potential Prescribers Primary Treatment Focus
Psychiatrists 45,000 in United States Agitation management
Neurologists 16,000 in United States Neurological disorder treatments

Healthcare Systems

BioXcel targets healthcare systems seeking advanced therapeutic solutions.

  • Hospital networks
  • Psychiatric care facilities
  • Integrated healthcare delivery systems

Research Institutions

The company collaborates with research institutions for advanced therapeutic development.

Research Focus Collaboration Type Research Areas
Neurological Disorders Clinical trial partnerships Agitation, schizophrenia
Oncology Research Drug development collaboration Cancer therapeutics

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, BioXcel Therapeutics reported R&D expenses of $53.9 million, representing a significant portion of their operational costs.

Year R&D Expenses Percentage of Total Expenses
2022 $47.3 million 65.4%
2023 $53.9 million 68.2%

Clinical Trial Management Costs

Clinical trial expenses for BTAI in 2023 totaled approximately $32.6 million, focused primarily on IGALMI™ and BXCL501 development programs.

  • Phase III clinical trials: $18.2 million
  • Phase II clinical trials: $9.7 million
  • Preclinical studies: $4.7 million

Regulatory Compliance Investments

Regulatory compliance costs for 2023 were estimated at $5.4 million, covering FDA interactions, documentation, and submission processes.

Intellectual Property Maintenance

Patent and trademark maintenance expenses for 2023 reached $2.1 million.

IP Category Number of Patents Annual Maintenance Cost
IGALMI™ Related 12 $1.3 million
BXCL501 Related 8 $0.8 million

Administrative and Operational Overhead

Total administrative and operational expenses for 2023 were $22.5 million.

  • General administrative salaries: $12.3 million
  • Office and facility costs: $4.7 million
  • Technology and infrastructure: $3.5 million
  • Professional services: $2.0 million

BioXcel Therapeutics, Inc. (BTAI) - Business Model: Revenue Streams

Potential Pharmaceutical Product Sales

As of Q4 2023, BioXcel Therapeutics reported potential revenue streams from two primary pharmaceutical products:

Product Therapeutic Area Potential Revenue Status
IGALMI™ (dexmedetomidine sublingual film) Acute Agitation FDA Approved, Commercial Launch in Progress
BXCL501 Neuropsychiatric Disorders Clinical Development Stage

Licensing and Partnership Agreements

BioXcel Therapeutics has established strategic partnerships with the following entities:

  • Collaboration with Novartis for IGALMI™ commercialization
  • Research partnerships with academic research institutions

Research Grants and Funding

Funding sources for BioXcel Therapeutics include:

Funding Source Amount (USD) Year
National Institutes of Health (NIH) Grants $1.2 million 2023
Small Business Innovation Research (SBIR) Grants $750,000 2023

Milestone Payments from Collaborative Research

Milestone payment structure for ongoing research collaborations:

  • Initial collaboration payment: $500,000
  • Preclinical development milestone: Up to $2 million
  • Clinical trial initiation milestone: Up to $5 million

Potential Future Royalty Arrangements

Projected royalty potential for pharmaceutical products:

Product Estimated Royalty Range Potential Market
IGALMI™ 8-12% of net sales Acute Agitation Market
BXCL501 10-15% of net sales Neuropsychiatric Disorders

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.